Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
28 patients (median age, 64 years [IQR, 57-69 years]); 86% males,75% BCLC 0-A) with 37 HCC tumors, complete, extensive and partial pathologic necrosis were achieved in 27/37(73%), 8/37(22%) and 2/37(5%) tumors, respectively.
I · Intervention 중재 / 시술
90Y-TARE with resin microspheres before liver transplantation or surgery
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
All tumors with a mean tumor absorbed dose ≥ 433 Gy achieved CPN. [CLINICAL TRIAL NUMBER] not applicable.
[PURPOSE] To evaluate the pathologic outcomes of 90Y-TARE of HCC with resin microspheres prescribed using the single-compartment model and to correlate posttreatment dose with outcomes.
- p-value P = 0.03
- p-value P = 0.048
- 95% CI 0.9-1
APA
Sarwar A, Nasser I, et al. (2026). Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres.. European journal of nuclear medicine and molecular imaging, 53(2), 876-889. https://doi.org/10.1007/s00259-025-07471-0
MLA
Sarwar A, et al.. "Histopathologic outcomes of hepatocellular carcinoma treated with transarterial radioembolization with yttrium-90 resin microspheres.." European journal of nuclear medicine and molecular imaging, vol. 53, no. 2, 2026, pp. 876-889.
PMID
40762798 ↗
Abstract 한글 요약
[PURPOSE] To evaluate the pathologic outcomes of 90Y-TARE of HCC with resin microspheres prescribed using the single-compartment model and to correlate posttreatment dose with outcomes.
[METHODS] This retrospective single-center study included adult patients with HCC who underwent 90Y-TARE with resin microspheres before liver transplantation or surgery. Histopathologic evaluation of liver tissue was performed. Complete pathologic necrosis (CPN) was defined as 100% tumor necrosis, extensive necrosis as 50-99%, and partial necrosis as < 50%. Posttreatment voxel-based dosimetry was conducted. Additional subgroup analysis was done to compare tumors with complete and incomplete necrosis.
[RESULTS] Among 28 patients (median age, 64 years [IQR, 57-69 years]); 86% males,75% BCLC 0-A) with 37 HCC tumors, complete, extensive and partial pathologic necrosis were achieved in 27/37(73%), 8/37(22%) and 2/37(5%) tumors, respectively. Tumors with CPN were significantly smaller than those without CPN (2.2 vs. 3.4 cm, P = 0.03), with longer interval between the 90Y-TARE and liver surgery (274 vs. 143 days, P = 0.048). All tumors with a mean tumor absorbed dose ≥ 433 Gy had CPN. Conversely, all tumors in which 4% or more of the tumor volume received a dose less than 100 Gy had incomplete necrosis. ROC analysis identified D95 ≥ 133 Gy (AUC 0.96 [95%CI: 0.9-1]) and V0-100 (%) < 5% (AUC 0.9 [95%CI: 0.75-0.97]) as predictors of CPN with 100% and 78% specificity, respectively.
[CONCLUSION] Among HCC patients who underwent 90Y-TARE with resin microspheres, 73% achieved complete pathologic necrosis. All tumors with a mean tumor absorbed dose ≥ 433 Gy achieved CPN.
[CLINICAL TRIAL NUMBER] not applicable.
[METHODS] This retrospective single-center study included adult patients with HCC who underwent 90Y-TARE with resin microspheres before liver transplantation or surgery. Histopathologic evaluation of liver tissue was performed. Complete pathologic necrosis (CPN) was defined as 100% tumor necrosis, extensive necrosis as 50-99%, and partial necrosis as < 50%. Posttreatment voxel-based dosimetry was conducted. Additional subgroup analysis was done to compare tumors with complete and incomplete necrosis.
[RESULTS] Among 28 patients (median age, 64 years [IQR, 57-69 years]); 86% males,75% BCLC 0-A) with 37 HCC tumors, complete, extensive and partial pathologic necrosis were achieved in 27/37(73%), 8/37(22%) and 2/37(5%) tumors, respectively. Tumors with CPN were significantly smaller than those without CPN (2.2 vs. 3.4 cm, P = 0.03), with longer interval between the 90Y-TARE and liver surgery (274 vs. 143 days, P = 0.048). All tumors with a mean tumor absorbed dose ≥ 433 Gy had CPN. Conversely, all tumors in which 4% or more of the tumor volume received a dose less than 100 Gy had incomplete necrosis. ROC analysis identified D95 ≥ 133 Gy (AUC 0.96 [95%CI: 0.9-1]) and V0-100 (%) < 5% (AUC 0.9 [95%CI: 0.75-0.97]) as predictors of CPN with 100% and 78% specificity, respectively.
[CONCLUSION] Among HCC patients who underwent 90Y-TARE with resin microspheres, 73% achieved complete pathologic necrosis. All tumors with a mean tumor absorbed dose ≥ 433 Gy achieved CPN.
[CLINICAL TRIAL NUMBER] not applicable.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.